Selzentry

MVC maraviroc

Recommended as component of ART for treatment of CCR5-tropic virus in treatment-experienced people
Entry Inhibitor

Standard Dose

The recommended dose varies depending on other medications being taken but will be either 150, 300, or 600 mg twice daily (available in 150 mg and 300 mg tablets). Can be taken without regard to food. Approved for adults and children weighing at least 4.4 pounds (2 kg) and having a creatinine clearance of at least 30 mL/min (measurement of kidney function); dose depends on weight. Available in a 20 mg/mL oral solution as well as 25 mg and 75 mg tablets. Selzentry for children is dosed based on body weight. See the package insert or DHHS guidelines for weight-based dosing. The oral solution should be administered using the included press-in bottle adapter and oral dosing syringe. Must be taken in combination with another antiretroviral(s).

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Before starting Selzentry, a specific blood test called a Trofile is required to determine if this medication will work.
  •  See package insert for more complete information on potential side effects and interactions.

Manufacturer

ViiV Healthcare
viivhealthcare.com; selzentry.com
(877) 844-8872

AWP

150 mg, 60 tablets: $1,867.44/month
300 mg, 60 tablets: $1,867.44/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments